Lundbeck’s research will in future concentrate on three main areas of biology: neurodegeneration, neuroinflammation and synaptic transmission. These areas are relevant to a wide range of brain disorders, including depression, schizophrenia, Parkinson’s, Alzheimer’s and Huntington’s diseases.
O.K. so the cynic inside me is worried about why Lundbeck is concentrating on these particular diseases?
Is it because they will never have to answer to anyone as to the side effects of their medication?
Any adverse reaction with these poor unfortunate patients could just as easily be put down to the illness! (Just like they tried to do with Shane)
The article below serves as an example of Lundbecks questionable practices…
May 10, 2003
The Danish drug company Lundbeck breached the UK industry code of practice in the way it advertised the successor to its top selling product, the antidepressant citalopram (Cipramil), the drug industry’s watchdog has ruled. The company claimed that its new offering, escitalopram (Cipralex), was more effective than citalopram, even though the two drugs have exactly the same active ingredient.
Escitalopram reached the market in June last year, just as citalopram’s British patent ran out and the first generic competitor went on sale in Germany. The new drug is identical to the old one, except that an inert isomer has been removed from the formulation. Critics contend that this practice is designed to win a new patent without the need to develop a genuinely new drug. Can they be trusted?????